🧪
hypothesis

LXR Agonism (H4): Microglial Lipid Efflux Promotion

Hypothesis

LXR Agonism (H4): Microglial Lipid Efflux Promotion

GW3965-mediated LXR activation promotes cholesterol efflux via ABCA1/ABCG1, enabling microglia to handle increased neuronal-derived lipid load without inflammatory activation.
🧬 NR1H3 (LXRα/NR1H3)🩺 neurodegeneration🎯 Composite 58%💱 $0.55▼6.1%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates 3 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.65 (15%) Evidence 0.62 (15%) Novelty 0.60 (12%) Feasibility 0.55 (12%) Impact 0.50 (12%) Druggability 0.70 (10%) Safety 0.35 (8%) Competition 0.60 (6%) Data Avail. 0.65 (5%) Reproducible 0.68 (5%) KG Connect 0.50 (8%) 0.580 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite58%

🧪 Overview

GW3965-mediated LXR activation promotes cholesterol efflux via ABCA1/ABCG1, enabling microglia to handle increased neuronal-derived lipid load without inflammatory activation. Amplifies compensatory anti-inflammatory response. Significant systemic toxicity concerns (hepatic steatosis, hypertriglyceridemia) and isoform non-selectivity limit translational potential.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Target Gene: NR1H3 LXR/NR1H3"]
    B["Molecular Mechanism<br/>Pathway Activation"]
    C["Cellular Phenotype<br/>Neuronal / Glial Response"]
    D["Network Effect<br/>Circuit-Level Consequence"]
    E["Disease Relevance<br/>Neurodegeneration Link"]
    A --> B --> C --> D --> E
    style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style E fill:#1b5e20,stroke:#81c784,color:#81c784

⚖️ Evidence

⚖️ Evidence Matrix3 supports3 contradicts
Supports
LXR agonism promotes microglial anti-inflammatory phenotype
PMID:28386024
Supports
ABCA1-dependent cholesterol efflux suppresses NLRP3 inflammasome
PMID:25713084
Supports
LXRβ in microglia protects against neurodegeneration
PMID:25446954
Contradicts
GW3965 induces hepatic steatosis and hypertriglyceridemia via SREBP1c activation
PMID:none
Contradicts
GW3965 activates both LXRα and LXRβ; non-selective activation increases systemic toxicity
PMID:none
Contradicts
LXR agonism does not reduce neuronal lipid secretion; microglia must continuously handle same load
PMID:none
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — NR1H3

No curated PDB or AlphaFold mapping for NR1H3 yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for NR1H3 (LXRα/NR1H3) from GTEx v10.

Nucleus accumbens basal ganglia6.7 Substantia nigra6.1 Caudate basal ganglia6.0 Cortex5.6 Cerebellum5.4 Frontal Cortex BA95.3 Putamen basal ganglia5.1 Anterior cingulate cortex BA245.0 Cerebellar Hemisphere4.8 Amygdala4.7 Hypothalamus4.4 Spinal cord cervical c-14.3 Hippocampus3.6median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for NR1H3 (LXRα →

No DepMap CRISPR Chronos data found for NR1H3 (LXRα.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

💰 Estimated Development
Cost
$0
Timeline

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▼ 0.2%
Volatility
Low
0.0057
Events (7d)
2
Price History
▼6.1%

💾 Resource Usage

LLM Tokens
11,236
$0.0337
Total Cost
$0.0337

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF C57BL/6J mice with established tau pathology (PS19 model) receive daily intraperitoneal GW3965 (10 mg/kg) for 4 weeks, THEN microglial ABCA1/ABCG1 expression will increase ≥2-fold in isolated CD11bMicroglial ABCA1/ABCG1 expression increases ≥2-fold; hippocampal extracellular cholesterol (assessed by LDL receptor expression as proxy) rises by ≥30% indicati— no observation —pending0.65
IF female 5xFAD mice receive oral GW3965 (15 mg/kg BID) for 8 weeks, THEN hippocampal IBA1+ microglial coverage of amyloid plaques will increase ≥40% and plasma TNF-α will decrease ≥50%, WHILE hepaticEnhanced microglial peri-plaque coverage (indicating improved lipid handling capacity) and reduced systemic inflammation, but with hepatotoxicity evidenced by h— no observation —pending0.55
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF C57BL/6J mice with established tau pathology (PS19 model) receive daily intraperitoneal GW3965 (10 mg/kg) for 4 weeks, THEN microglial ABCA1/ABCG1 expression will increase ≥2-fold in isolated CD11b+ cells and hippocampal cholesterol efflux will be elevated compared to vehicle-treated controls wit
Predicted outcome: Microglial ABCA1/ABCG1 expression increases ≥2-fold; hippocampal extracellular cholesterol (assessed by LDL receptor expression as proxy) rises by ≥30
Falsification: No significant change in microglial ABCA1/ABCG1 mRNA/protein (fold change <1.5) or no elevation in cholesterol efflux markers in the GW3965 group versus vehicle after 4 weeks of treatment.
pendingconf 55%
IF female 5xFAD mice receive oral GW3965 (15 mg/kg BID) for 8 weeks, THEN hippocampal IBA1+ microglial coverage of amyloid plaques will increase ≥40% and plasma TNF-α will decrease ≥50%, WHILE hepatic triglyceride content will increase ≥2-fold compared to vehicle-treated 5xFAD mice within 10 weeks o
Predicted outcome: Enhanced microglial peri-plaque coverage (indicating improved lipid handling capacity) and reduced systemic inflammation, but with hepatotoxicity evid
Falsification: If microglial peri-plaque coverage does not increase (≤20% change) or if plasma TNF-α does not decrease despite ABCA1/ABCG1 upregulation, the anti-inflammatory lipid efflux mechanism is not supported.
View on SciDEX ↗